Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. LDOS
8. HUM
9. CSCO
10. KTOS

Go back to Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results

Piper Jaffray Remains Sidelined on Sangamo Biosciences (SGMO) Following 4Q Report

February 28, 2017 12:01 PM EST

Piper Jaffray reiterated a Neutral rating and $5.00 price target on Sangamo BioSciences (NASDAQ: SGMO) following the company's 4Q earnings report. Sangamo reported 4Q16 revenues of $8.9M, slightly above projections, and opex of $18.8M, slightly below projections.

Analyst Charles Duncan commented, "Today Sangamo reported 4Q16 financial... More

Sangamo Biosciences (SGMO) Tops Q4 EPS by 11c

February 28, 2017 7:02 AM EST

Sangamo Biosciences (NASDAQ: SGMO) reported Q4 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $8.9 million versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.

... More